Design an opioid use disorder perioperative care bundle spanning optimization, pain…
- User
Design an opioid use disorder perioperative care bundle spanning optimization, pain strategies, and recovery support.
Assistant
1. Analyze the Request: * Topic: Perioperative care bundle for Opioid Use Disorder (OUD). * Scope: Optimization (pre-op), Pain Strategies (intra-op/immediate post-op), and Recovery Support (post-op/discharge). * Goal: Design a comprehensive, clinical, and practical guide/bundle.
-
Target Audience & Tone:
- Audience: Healthcare providers (surgeons, anesthesiologists, nurses, pain specialists, addiction medicine specialists).
- Tone: Professional, evidence-based, non-stigmatizing, patient-centered.
-
Structure of the "Bundle":
- A "bundle" usually implies a set of distinct, evidence-based elements that, when implemented together, produce better outcomes than individual elements.
- I need to organize this chronologically:
- Phase 1: Pre-operative Optimization (Preparation).
- Phase 2: Intra-operative Management (The Surgery).
- Phase 3: Post-operative Care (Acute Pain Management).
- Phase 4: Transition & Recovery (Discharge & Follow-up).
-
Fleshing out Phase 1: Pre-operative Optimization:
- Key concept: Identification and stigma reduction.
- Screening: Universal screening? Yes.
- Medication for Opioid Use Disorder (MOUD): This is critical. Methadone, Buprenorphine, Naltrexone.
- Rule: Do not stop MOUD. Continue it.
- Naltrexone issue: Needs to be stopped prior to surgery if opioids are needed for pain (antagonist). Planning is key.
- Anxiety/Expectations: Manage expectations regarding pain. It will not be zero pain, but manageable pain.
- Planning: Multi-modal plan.
-
Fleshing out Phase 2: Intra-operative Management:
- Key concept: Minimize opioid exposure while ensuring analgesia.
- Regional Anesthesia: Nerve blocks, epidurals, spinal. Absolute priority.
- Multimodal Analgesia (Non-opioid): Ketamine (great for tolerance), Lidocaine, Magnesium, Dexmedetomidine, NSAIDs/Acetaminophen.
- Opioid use: High tolerance means they need more for breakthrough intra-op, but we want to minimize the total.
-
Fleshing out Phase 3: Post-operative Care (In-hospital):
- Key concept: Regain control.
- MOUD: Continue! (Ideally, coordinate with the patient's prescriber).
- Pain Assessment: Subjective scales are tricky (tolerance). Focus on function ("Can you cough/walk?").
- Multimodal: Continue Ketamine, NSAIDs, etc.
- Short-acting opioids: If needed, use as needed (PRN) rather than around the clock (ATC) if possible, or bridge with patient-controlled analgesia (PCA) but with caution and limits.
- Stigma: Avoid "drug seeking" labeling; differentiate between pseudoaddiction (inadequate pain relief) and relapse.
-
Fleshing out Phase 4: Transition & Recovery Support:
- Key concept: Safety and Relapse Prevention.
- Discharge Prescribing: Only what is needed. No "just in case" #30 pills. Preferably 3-5 days max.
- Tapering: Plan to get back to baseline MOUD dose (or slightly higher for a brief period if needed, then taper).
- Naloxone: Prescribe co-dispense.
- Follow-up: Close follow-up with addiction specialist.
-
Refining and Formatting:
- Use bold headings and bullet points for readability.
- Create a "Core Principles" section to frame the mindset (Harm Reduction, Continuity of Care).
- Include a specific section on "Special Considerations" (e.g., the patient on Naltrexone vs. Buprenorphine). This is a common pitfall.
- Self-Correction during drafting: I initially thought about stopping Buprenorphine. Correction: Current guidelines suggest continuing Buprenorphine and adding full agonist opioids on top if needed, rather than stopping it (which risks relapse). I need to make this clear.
-
Drafting the Content (Mental or rough notes):
- Pre-op: Consult Addiction Med. Confirm MOUD dose. Don't stop it.
- Intra-op: Blocks, blocks, blocks. Ketamine infusion.
- Post-op: Non-opioid schedule. Opioids for breakthrough only.
- Discharge: Naloxone kit. Taper plan. Warm handoff to outpatient.
-
Final Polish:
- Ensure the language is clinical yet empathetic.
- Add a disclaimer (medical advice).
- Organize into the requested three categories (Optimization, Pain Strategies, Recovery) but keep the chronological flow within them.
-
Final Output Generation: (This matches the provided good response).
- Structure:
- Guiding Principles.
- Phase 1: Optimization (Pre-op).
- Phase 2: Pain Strategies (Intra-op/Post-op).
- Phase 3: Recovery Support (Discharge).
- Special Considerations (Naltrexone).
- Structure:
(Self-Correction Example during the process): Thought: Should I mention specific morphine milligram equivalents (MME)? Decision: No, that varies too much by surgery. Better to emphasize "lowest effective dose" and "shortest duration." Thought: What if they aren't on MOUD? Decision: Offer to start MOUD pre-op if possible, or ensure they have counseling resources. Add a point about "Opportunity for MOUD initiation."
- Final Review against User Prompt:
- Optimization? Yes.
- Pain Strategies? Yes.
- Recovery Support? Yes.
This thought process moves from understanding the requirements to structuring the clinical content, refining the medical accuracy (especially regarding MOUD), and formatting for clarity. This perioperative care bundle is designed for patients with Opioid Use Disorder (OUD), including those on Medication for OUD (MOUD) and those with active use.
The core principle of this bundle is harm reduction and continuity of care: untreated pain leads to relapse, and stigma leads to under-treatment.
Here is a comprehensive care bundle divided into three phases.
I. Phase 1: Optimization (Pre-Operative)
Goal: Establish a baseline, build rapport, and prevent withdrawal.
1. Stigma-Free Screening & History
- Universal Approach: Do not target based on appearance. Use universal screening tools.
- Detailed History: Document current opioid use (illicit and prescribed), timing of last dose, and history of tolerance/confusion/oversedation.
- Verify MOUD Status: Contact the patient’s prescriber or Opioid Treatment Program (OTP) to confirm the current dose of Methadone or Buprenorphine. Do not stop MOUD.
2. Medical Optimization
- Risk Stratification: Assess for cardiac issues (prolonged QTc in Methadone users) and respiratory compromise.
- Counseling: If the patient is not currently in treatment, offer a "warm handoff" to addiction medicine pre-operatively. This is a "reachable moment."
3. Patient Education & Expectation Management
- The "Third Bucket" Conversation: Explain to the patient that they have a high tolerance. Explain that complete painlessness (0/10) is unlikely and unsafe to attempt.
- Goal Setting: Agree on a functional pain goal (e.g., pain low enough to sleep and participate in PT).
- Reassurance: Explicitly state: "We will not let you go into withdrawal."
II. Phase 2: Pain Strategies (Intra-Op & Acute Post-Op)
Goal: Maximize non-opioid modalities (Multimodal Analgesia) and safely bridge with opioids if needed.
1. Continuation of MOUD (Critical)
- Methadone/Buprenorphine: Continue the home dose on the day of surgery and throughout the admission. Stopping these drugs induces withdrawal and hyperalgesia (increased pain sensitivity).
- Naltrexone (Vivitrol): If the patient is on injectable naltrexone, recognize that they are opioid-blocked. High-dose opioids will not work. Rely 100% on Regional Anesthesia and Non-Opioid IV/PO meds (Ketamine, Lidocaine, NSAIDs).
2. Regional Anesthesia (The Gold Standard)
- Neuraxial & Nerve Blocks: Prioritize epidurals, spinals, and nerve blocks over general anesthesia whenever possible.
- Additives: Use adjuncts in blocks (Dexamethasone, Clonidine, Dexmedetomidine) to prolong duration.
3. Multimodal "Non-Opioid" Backbone
- Scheduled Acetaminophen & NSAIDs: Unless contraindicated, give around the clock.
- NMDA Antagonists: Utilize IV Ketamine (low-dose infusion) or IV Magnesium to treat hyperalgesia and tolerance.
- IV Lidocaine: Consider for visceral pain and anti-inflammatory effects.
- Adjuncts: Gabapentinoids (Caution with sedation/respiratory depression when combined with opioids).
4. Opioid Strategy (The "Bridge")
- Avoid Pure Agonists on Buprenorphine: While you can override Buprenorphine with high-dose fentanyl, it is difficult. It is safer to continue Buprenorphine and use Potent Short-Acting Opioids (e.g., Hydromorphone) for breakthrough pain if non-opioids fail.
- Avoid PCA (Patient Controlled Analgesia): PCAs carry a high risk of error in opioid-tolerant patients. Use nurse-administered boluses or careful oral titration.
- Tolerance Acknowledgement: The patient will require higher doses than an opioid-naïve patient to achieve the same effect. Base doses on previous intake, not "standard" orders.
III. Phase 3: Recovery Support (Discharge & Transition)
Goal: Prevent relapse and overdose.
1. Safe Discharge Prescribing
- Limit Supply: Prescribe only the amount needed for the acute recovery phase (e.g., 3–7 days), not a 30-day supply.
- Avoid Mixed Agonist-Antagonists: Do not prescribe Tramadol, Codeine, or Nubain. These can precipitate withdrawal in MOUD patients.
- Fentanyl Test Strips: For patients with active illicit use, consider distributing fentanyl test strips along with Naloxone at discharge.
2. Naloxone Co-Prescribing
- Mandatory: Every patient with OUD (and ideally their family/caregiver) should leave with a Naloxone (Narcan) kit and instructions on how to use it.
3. The Taper Plan
- Explicit Instructions: Provide a written taper schedule. The patient should return to their baseline MOUD dose (or baseline illicit use level) as the surgical pain subsides.
- Avoid Escalation: Monitor closely to ensure acute pain management does not unintentionally escalate into a higher maintenance dose.
4. Care Coordination
- Notify Prescriber: Send discharge summary and opioid prescription details to the patient’s addiction specialist/OTP.
- Follow-up: Schedule a follow-up with addiction medicine within 1–2 weeks post-discharge.
Summary Checklist for Providers
- Do not stop Methadone or Buprenorphine.
- Do place a nerve block if possible.
- Do use Ketamine/Magnesium for tolerance.
- Do prescribe Naloxone.
- Do not judge the patient for requiring higher opioid doses; it is physiology, not "drug seeking."
-
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.